Unknown

Dataset Information

0

Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.

ABSTRACT: Immuno-oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients.

SUBMITTER: Huck BR 

PROVIDER: S-EPMC5900885 | biostudies-other | 2018 Apr

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Small Molecules Drive Big Improvements in Immuno-Oncology Therapies.

Huck Bayard R BR   Kötzner Lisa L   Urbahns Klaus K  

Angewandte Chemie (International ed. in English) 20180222 16

Immuno-oncology therapies have the potential to revolutionize the armamentarium of available cancer treatments. To further improve clinical response rates, researchers are looking for novel combination regimens, with checkpoint blockade being used as a backbone of the treatment. This Review highlights the significance of small molecules in this approach, which holds promise to provide increased benefit to cancer patients. ...[more]

Similar Datasets

Unknown Immuno-Oncology: Emerging Targets and Combination Therapies.
| S-EPMC6115503 | biostudies-literature
Unknown Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.
| S-EPMC7444785 | biostudies-literature
Unknown The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma.
| S-EPMC7826922 | biostudies-literature
Unknown Personalized Immuno-Oncology.
| S-EPMC7923844 | biostudies-literature
Unknown Exosomal miRNA: Small Molecules, Big Impact in Colorectal Cancer.
| S-EPMC6815599 | biostudies-literature
Transcriptomics AVA-ADR-001- a small molecular inhibitor of ADAR1 (Immuno-oncology target)
2023-04-17 | GSE229503 | GEO
Unknown Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.
| S-EPMC8795065 | biostudies-literature
Unknown Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations.
| S-EPMC6830404 | biostudies-literature
Unknown Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
| S-EPMC7481145 | biostudies-literature
Unknown The Role of Radiation Oncology in Immuno-Oncology.
| S-EPMC6394774 | biostudies-literature